Not provided
Not provided
Not provided
Not provided
Due to COVID19 Pandemic effect on 2020.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Stimulation protocols for IVF underwent several cycles of upgrading aiming to achieve reasonable outcomes with low-cost cycles. Antagonist protocols have been introduced as effective and comparable to long agonist regarding the outcomes. However, these protocols are still costly. Alternative protocols using progestin suppressions appear options for consideration.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dydrogesterone Suppression | Experimental | Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent luteinizing hormone (LH) surge. The stimulation is with 150-300 IU FSH/HMG starting on cycle day 2 and adjusted according to the AFC and AMH. |
|
| Dydrogesterone Suppression with minimal stimulation | Experimental | Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent LH surge. The stimulation is with clomifene citrate 50 mg three times daily with150 IU FSH starting on cycle day 2 and continued every other day and adjusted according to the AFC and AMH. |
|
| Antagonist Suppression | Active Comparator | cetrorelix acetate 0.25 started on stimulation day 6 till the trigger day to prevent LH surge. The stimulation is with150-300 IU FSH starting on cycle day 2 and continued daily and adjusted according to the AFC and AMH. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LH Suppression | Drug | Stimulation protocols |
|
| Measure | Description | Time Frame |
|---|---|---|
| Live Birth after first Vitrified-warmed cycle | Delivery of one or more viable infants > 20th weeks of gestation | 42 weeks of gestation |
| Measure | Description | Time Frame |
|---|---|---|
| Biochemical pregnancy | positive human chorionic Gonadotrophin (βhCG) ≥ 10 IU/L | 14 days after egg retrieval |
| Clinical pregnancy | registered sacs with a heartbeat on ultrasound at 7th weeks of gestation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mohamed Fawzy | Ibnsina Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Banon Fertility Center | Asyut | Egypt | ||||
| IbnSina IVF Center, IbnSina Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007246 | Infertility |
| ID | Term |
|---|---|
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| within 12 weeks of gestation |
| Ongoing pregnancy | continued viable pregnancy > 20th weeks of gestation | within 24 weeks of pregnancy |
| Miscarriage | loss of pregnancy ≤ 20th weeks of gestation | Within 20 weeks of pregnancy |
| Term live-birth for vitrified-warmed transfer | Delivery of one or more viable infants ≥37 weeks of gestation | Within 42 weeks of gestation |
| Preterm Birth | delivery of one or more viable infants < 37th weeks of gestation | Within 42 weeks of gestation |
| Very preterm birth | delivery of one or more viable infants < 32nd weeks of gestation | Within 42 weeks of gestation |
| Low birth weight babies | Babies with < 2500 gm | Within 24 hours of delivery |
| Congenital malformation | delivery of congenitally malformed babies | Within one month of delivery |
| Still birth | delivery of nonviable babies > 20 weeks of gestation | Within 42 weeks of gestation |
| Cumulative live birth | Registered viable neonates after two vitrified-warmed transfers within one year of randomization | One year from randomization |
| Fertilization | presence of 2 pronuclei 17±1 hr after oocyte injection | Within 6 days of culture |
| Embryo cleavage | Cleaved embryos per fertilized oocyte | Within 6 days of culture |
| Top-quality embryo on day 3 | (7-8 cells with appropriate-sizes blastomeres and less than 10% fragmentation by volume | Within 6 days of culture |
| Blastocyst formation on day 5 or 6 | formed blastocysts per fertilized oocyte | Within 6 days of culture |
| Top-quality blastocyst on day 5 | Rounded and dense inner cell mass with many trophectodermal cells creating a connected zone and a blastocoel more than 100% by volume; ≥ 311 grade per fertilized oocyte | Within 6 days of culture |
| Cryopreservation | Cryopreserved embryos per fertilized oocyte | Within 6 days of culture |
| Live-birth-implantation rate | Number of viable neonates per number of embryos transferred | Within 42 weeks of gestation |
| Utilized embryos | Number of cryopreserved plus transferred embryos per fertilized oocyte | Within 6 days of culture |
| Top-quality utilized embryos | Number of high-quality embryos transferred plus cryopreserved per fertilized oocyte | Within 6 days of culture |
| Metaphase II oocyte | Mature oocyte per oocyte collected | Within 24 hours of oocyte retrieval |
| Sohag |
| 12345 |
| Egypt |
| AlRahma Hospital | Sohag | Egypt |